Hit enter to search or ESC to close

News

Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting

Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is today releasing interim clinical data of its Phase 1 clinical trial program for its investigative drug PBT434 at the American Academy of Neurology Annual Meeting in Philadelphia, USA. The Platform Presentation titled: A First in Human Study of PBT434, a Novel Small Molecule Inhibitor ...

Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting

Alterity Therapeutics Limited, (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) will present clinical data from its lead drug candidate PBT434 at the American Academy of Neurology Annual Meeting in Philadelphia, USA, from 5-9th May 2019. Alterity will feature prominently at the Annual Meeting with a Platform Presentation on Sunday 5thMay featuring data from the company’s ...

Change of Company Name

We wish to announce the Company name change has been processed by the Australian Securities and Investment Commission and the Company has changed its name from “Prana Biotechnology Limited” to “Alterity Therapeutics Limited”.

Receive news from Alterity Therapeutics